NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
63187-0693-30 | 63187-0693 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Apr 1, 2016 | In Use | |
59651-0544-60 | 59651-0544 | DASATINIB | DASATINIB | 70.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Apr 22, 2025 | In Use | |
00085-4348-01 | 00085-4348 | Peginterferon alfa-2b | Sylatron | Immunotherapy | Cytokine | Interferon | Mar 29, 2011 | Oct 18, 2020 | In Use | ||
54569-6208-02 | 54569-6208 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | May 10, 2016 | In Use | |
00310-1350-30 | 00310-1350 | Osimertinib | Tagrisso | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Nov 13, 2015 | In Use | |
23155-0550-31 | 23155-0550 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Nov 9, 2015 | In Use | |
52958-0046-10 | 52958-0046 | Octreotide acetate | OCTREOTIDE ACETATE | 100.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | May 2, 2024 | In Use | ||
71205-0729-14 | 71205-0729 | PREDNISONE | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec 12, 2022 | In Use | |
00143-9218-01 | 00143-9218 | Idarubicin Hydrochloride | Idarubicin Hydrochloride | 1.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Jan 30, 2017 | In Use | |
25000-0011-03 | 25000-0011 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Apr 27, 2017 | In Use | |
68788-7102-09 | 68788-7102 | ESTRADIOL | ESTRADIOL | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Mar 12, 2018 | In Use | ||
55513-0006-01 | 55513-0006 | Darbepoetin alfa | Aranesp | 200.0 ug/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Sep 11, 2006 | In Use | ||
71335-1525-02 | 71335-1525 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec 4, 2018 | In Use | |
25021-0247-50 | 25021-0247 | Cyclophosphamide | Cyclophosphamide | 500.0 mg/25mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Jan 15, 2024 | In Use | |
00480-9259-08 | 00480-9259 | Octreotide Acetate | Octreotide Acetate | 3.33 mg/ml | Hormonal Therapy | Somatostatin Analog | Intramuscular | Oct 1, 2024 | In Use | ||
66993-0844-35 | 66993-0844 | Prednisolone Sodium Phosphate | Prednisolone Sodium Phosphate | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Oct 1, 2020 | Sep 30, 2025 | In Use |
68788-8377-03 | 68788-8377 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Feb 28, 2023 | In Use | |
72789-0473-21 | 72789-0473 | PredniSONE | PredniSONE Tablets, USP, 20 mg | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 12, 2025 | In Use | |
50419-0171-06 | 50419-0171 | Regorafenib | Stivarga | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGF, FGF, PDGFR, KIT, RET, TIE2, DDR2, TrkQ, RAF, BRAF, SAPK2, PTK, Abl | Oral | May 1, 2021 | In Use | |
55513-0021-04 | 55513-0021 | Darbepoetin alfa | Aranesp | 40.0 ug/.4mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Aug 14, 2006 | In Use | ||
54868-4031-00 | 54868-4031 | Estradiol | Estradiol | 2.0 mg/1 | Hormonal Therapy | Estrogen | Oral | May 7, 2003 | In Use | ||
55648-0662-01 | 55648-0662 | Granisetron Hydrochloride | Granisetron Hydrochloride | 0.1 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Mar 3, 2008 | In Use | |
00078-0249-15 | 00078-0249 | Letrozole | Femara | 2.5 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Jul 31, 1997 | In Use | ||
55513-0098-04 | 55513-0098 | Darbepoetin alfa | Aranesp | 10.0 ug/.4mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Aug 26, 2006 | In Use | ||
00069-0277-02 | 00069-0277 | Doxorubicin Hydrochloride | Doxorubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Aug 19, 2024 | In Use |
Found 11564 results — Export these results